Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Kristy L. Richards"'
Autor:
Xiaoxiao Wang, Xin Cao, Ruifang Sun, Charlene Tang, Alexandar Tzankov, Jun Zhang, Ganiraju C. Manyam, Min Xiao, Yi Miao, Kausar Jabbar, Xiaohong Tan, Yuyang Pang, Carlo Visco, Yan Xie, Karen Dybkaer, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Ben M. Parsons, Jane N. Winter, Miguel A. Piris, Shaoying Li, Roberto N. Miranda, L. Jeffrey Medeiros, Yong Li, Zijun Y. Xu-Monette, Ken H. Young
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 6, Pp 574-593 (2018)
PTEN loss has been associated with poorer prognosis in many solid tumors. However, such investigation in lymphomas is limited. In this study, PTEN cytoplasmic and nuclear expression, PTEN gene deletion, and PTEN mutations were evaluated in two indepe
Externí odkaz:
https://doaj.org/article/c7fd7cb49cf3423f86e7e2e738231d1f
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching
Externí odkaz:
https://doaj.org/article/b75208d6641e4b62be73c3099d58aef3
Publikováno v:
PeerJ, Vol 1, p e31 (2013)
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab res
Externí odkaz:
https://doaj.org/article/c5da673c5f3542498e53bddb0138e4d2
Autor:
Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock
Publikováno v:
Journal of Health Economics and Outcomes Research
**Background:** Research has shown that treatment interruptions are associated with worse failure-free survival in chronic myeloid leukemia (CML); however they are commonly used in clinical trials to manage adverse events. **Objectives:** This study
Externí odkaz:
https://doaj.org/article/4aac16b651f8469baaa56e36b455935e
Autor:
Sandeep S. Davé, David B. Dunson, Jyotishka Datta, Yuan Zhuang, Shawn Levy, Cassandra Love, Anupama Reddy, Deepthi Rajagopalan, Jenny Zhang, Guojie Li, Nicholas S. Davis, Randy D. Gascoyne, Sandra Basic-Kinda, Igor Aurer, John R. Goodlad, William W. L. Choi, Gopesh Srivastava, Rex K.H. Au-Yeung, Amy Chadburn, Andrew M. Evens, Monika Pilichowska, Pierre Sujobert, Anne Moreau, Marie Parrens, Lucile Baseggio, Mayur Parihar, Anne W. Beaven, Christopher R. Flowers, Leon Bernal-Mizrachi, Steven Horwitz, Neha Mehta-Shah, Wing C. Chan, Dennis Weisenburger, Lawrence Low, Eric D. Hsi, Sarah L. Ondrejka, Yuri Fedoriw, Kristy L. Richards, Jennifer R. Chapman-Fredricks, Izidore S. Lossos, Magdalena B. Czader, Virginie Fataccioli, Marie Helene Delfau-Larue, Karim Belhadj, Javeed Iqbal, Tayla Heavican, Liqiang Xi, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, Alina Nicolae, Laurence De Leval, Marion Travert, Philippe Gaulard, Andrea B. Moffitt, Matthew McKinney
Supplementary Table S1. Sanger validated variants. Supplementary Table S2. Mutations in HSTL driver genes. Supplementary Table S3. Other mutations identified by exome sequencing. Supplementary Table S4. Copy number of HSTL patients and cell lines. Su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2977857d8e39de8241655319c2cafef
https://doi.org/10.1158/2159-8290.22532180
https://doi.org/10.1158/2159-8290.22532180
Autor:
Sandeep S. Davé, David B. Dunson, Jyotishka Datta, Yuan Zhuang, Shawn Levy, Cassandra Love, Anupama Reddy, Deepthi Rajagopalan, Jenny Zhang, Guojie Li, Nicholas S. Davis, Randy D. Gascoyne, Sandra Basic-Kinda, Igor Aurer, John R. Goodlad, William W. L. Choi, Gopesh Srivastava, Rex K.H. Au-Yeung, Amy Chadburn, Andrew M. Evens, Monika Pilichowska, Pierre Sujobert, Anne Moreau, Marie Parrens, Lucile Baseggio, Mayur Parihar, Anne W. Beaven, Christopher R. Flowers, Leon Bernal-Mizrachi, Steven Horwitz, Neha Mehta-Shah, Wing C. Chan, Dennis Weisenburger, Lawrence Low, Eric D. Hsi, Sarah L. Ondrejka, Yuri Fedoriw, Kristy L. Richards, Jennifer R. Chapman-Fredricks, Izidore S. Lossos, Magdalena B. Czader, Virginie Fataccioli, Marie Helene Delfau-Larue, Karim Belhadj, Javeed Iqbal, Tayla Heavican, Liqiang Xi, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, Alina Nicolae, Laurence De Leval, Marion Travert, Philippe Gaulard, Andrea B. Moffitt, Matthew McKinney
Supplementary Figure S1. Sanger sequencing chromatograms. Supplementary Figure S2. Cancer cell fraction for driver genes. Supplementary Figure S3. Ideogram with chromosome 7 alterations. Supplementary Figure S4. Examples of Exome Copy Number. Supplem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1096702833396e08e883c3e0ac18c2a4
https://doi.org/10.1158/2159-8290.22532186
https://doi.org/10.1158/2159-8290.22532186
Autor:
Ken H. Young, L. Jeffrey Medeiros, Miguel A. Piris, Jane N. Winter, Roberto N. Miranda, Carlo E. Bueso-Ramos, Michael B. Møller, John P. Farnen, Andrés J.M. Ferreri, Maurilio Ponzoni, Weiyun Ai, Jooryung Huh, J. Han van Krieken, William W. L. Choi, Eric D. Hsi, Kristy L. Richards, Jiayu Chen, Govind Bhagat, Youli Zu, Attilio Orazi, April Chiu, Karen Dybaer, Santiago Montes-Moreno, Ganiraju C. Manyam, Alexander Tzankov, Carlo Visco, Zijun Y. Xu-Monette, Ling Li, Chi Young Ok
PDF file - 57KB, Supplemental Table 1. Genes differently expressed in EBV+ DLBCL vs. EBV-negative DLBCL. A. Genes upregulated in EBV+ DLBCL; B. Genes downregulated in EBV+ DLBCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee282432e7b1205b561711efbc64803
https://doi.org/10.1158/1078-0432.22455290
https://doi.org/10.1158/1078-0432.22455290
Autor:
Ken H. Young, L. Jeffrey Medeiros, Miguel A. Piris, Jane N. Winter, Roberto N. Miranda, Carlo E. Bueso-Ramos, Michael B. Møller, John P. Farnen, Andrés J.M. Ferreri, Maurilio Ponzoni, Weiyun Ai, Jooryung Huh, J. Han van Krieken, William W. L. Choi, Eric D. Hsi, Kristy L. Richards, Jiayu Chen, Govind Bhagat, Youli Zu, Attilio Orazi, April Chiu, Karen Dybaer, Santiago Montes-Moreno, Ganiraju C. Manyam, Alexander Tzankov, Carlo Visco, Zijun Y. Xu-Monette, Ling Li, Chi Young Ok
PDF file - 3781KB, Supplemental Figure 1. Morphologic subtypes of EBV+ DLBCL. A, E, I, and M. The monomorphic subtype is composed of monotonous sheets of large transformed B-cells. B, F, J and N. The polymorphic subtype, canonical large B-cell neopla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189b93727456a2de257d750bb3313f43
https://doi.org/10.1158/1078-0432.22455293.v1
https://doi.org/10.1158/1078-0432.22455293.v1
Autor:
Eric Padron, D. Neil Hayes, Ahmet Zehir, Elli Papaemmanuil, Ross L. Levine, H. Shelton Earp, William Y. Kim, Juneko E. Grilley-Olson, Jared Weiss, John T. Soper, Todd C. Knepper, Christine M. Walko, Kristy L. Richards, Nirali M. Patel, Michele C. Hayward, Sean J. Yoder, Tania E. Mesa, Joel S. Parker, Kelly L. Bolton, Nathan D. Montgomery, Maria E. Balasis, Markus Ball, Jonathan S. Berg, Xianming Tan, Nancy K. Gillis, Catherine C. Coombs
Purpose:In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately reflect the burden of somatic mutations in the tumor being sequenced. Here, we sough
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc8a460255a9413c3920f646bb3a6eb
https://doi.org/10.1158/1078-0432.c.6527667.v1
https://doi.org/10.1158/1078-0432.c.6527667.v1
Autor:
Ken H. Young, L. Jeffrey Medeiros, Miguel A. Piris, Jane N. Winter, Roberto N. Miranda, Carlo E. Bueso-Ramos, Michael B. Møller, John P. Farnen, Andrés J.M. Ferreri, Maurilio Ponzoni, Weiyun Ai, Jooryung Huh, J. Han van Krieken, William W. L. Choi, Eric D. Hsi, Kristy L. Richards, Jiayu Chen, Govind Bhagat, Youli Zu, Attilio Orazi, April Chiu, Karen Dybaer, Santiago Montes-Moreno, Ganiraju C. Manyam, Alexander Tzankov, Carlo Visco, Zijun Y. Xu-Monette, Ling Li, Chi Young Ok
Purpose: Epstein–Barr virus–positive (EBV+) diffuse large B-cell lymphoma (DLBCL) of the elderly is a variant of DLBCL with worse outcome that occurs most often in East-Asian countries and is uncommon in the Western hemisphere. We studied the lar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae0342619b3ad137439af380835d639
https://doi.org/10.1158/1078-0432.c.6522977.v1
https://doi.org/10.1158/1078-0432.c.6522977.v1